Related Experiment Videos

A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase

H Kawakatsu1, T Sakai, Y Takagaki

  • 1Molecular Biology Department, Research Laboratories, Nippon Shinyaku Co. Ltd., 601 Kyoto, Japan.

Insights

A new antibody, clone 28, distinguishes the active form of c-Src kinase in vivo. This discovery enables visualization of active c-Src in cells and tissues, revealing its activation in platelets.

Area of Science:

  • Cellular Biology
  • Molecular Biology
  • Biochemistry

Background:

  • Regulation of c-Src kinase activity is crucial and involves phosphorylation/dephosphorylation of Tyr-530.
  • Distinguishing between active and inactive c-Src forms in vivo has been a significant challenge.
  • Previous methods could not differentiate c-Src states, limiting in vivo functional studies.

Purpose of the Study:

  • To develop a method for distinguishing active from inactive forms of c-Src kinase in vivo.
  • To characterize a novel monoclonal antibody that selectively recognizes the active form of c-Src.
  • To investigate the cellular and tissue distribution of the active c-Src form.

Main Methods:

  • Development and characterization of a new monoclonal antibody, clone 28, specific for active c-Src.
  • Peptide competition assays to determine antibody binding specificity.
  • Immunoprecipitation and Western blotting using clone 28 and mAb 327.
  • Cyanogen bromide cleavage and two-dimensional tryptic mapping.
  • Immunofluorescence microscopy in cultured cells and immunohistochemistry in mouse tissues.

Main Results:

  • Clone 28 selectively recognizes the active, non-phosphorylated Tyr-530 form of c-Src.
  • mAb 327 recognizes both active and inactive (phosphorylated Tyr-530) forms of c-Src.
  • Clone 28 demonstrates distinct localization of active c-Src in fibroblasts and highlights high activation in megakaryocytes within embryonic mouse liver tissue.

Conclusions:

  • Clone 28 provides the first tool to specifically detect the active form of c-Src in vivo.
  • The findings support the existence of multiple c-Src forms, as previously hypothesized.
  • Direct evidence shows high c-Src activation in platelets (megakaryocytes), opening new avenues for research.

Related Concept Videos